NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A Meeting Minutes

**Minutes:** Confirmed

**Date:** Tuesday 3 August 2021

**Location:** Via Zoom Teleconference

## Attendees

Committee members present

1. Dr Jane Adam (chair) Present for all Items
2. Dr Brian Shine (VIce-chaIr) Present for all Items
3. Dr Peter Baker Present for all Items
4. Richard Ballerand Items 1 to 5.2.2
5. Dr Craig Buckley Present for all Items
6. Dr Justin Daniels Present for all Items
7. Dr Steve Edwards Items 1 to 5.2.2
8. Rebecca Harmston Present for all Items
9. Prof. Khalida Ismail Items 1 to 6.1.3
10. Prof. G.J. Melendez-Torres Items 5 to 6.2.2
11. Giles Monnickendam Items 6 to 6.2.2
12. Stella O’Brien Items 6 to 6.2.2
13. Malcolm Oswald Present for all Items
14. Sarah Parry Present for all Items
15. Hugo Pedder Present for all Items
16. Dr Mohit Sharma Present for all Items
17. Min Ven Teo Items 1 to 5.1.3
18. Dr Alice Turner Items 5 to 6.2.2

NICE staff present

Janet Robertson, Associate Director Present for all Items

Thomas Feist, Project Manager Present for all Items

Joanna Richardson, Health Technology Assessment Adviser Items 1 to 4.2.2

Mary Hughes, Health Technology Assessment Adviser Items 1 to 5.2.2

Lorna Dunning, Health Technology Assessment Adviser Items 6 to 6.2.2

Albany Meikle, Health Technology Assessment Analyst Items 1 to 5.2.2

Ross Wilkinson, Health Technology Assessment Analyst Items 1 to 5.2.2

Marcela Haasova, Health Technology Assessment Analyst Items 1 to 5.2.2

Cara Gibbons, Health Technology Assessment Analyst Items 1 to 5.2.2

Jeremy Dietz, Health Technology Assessment Analyst Present for all Items

Catherine Spanswick, Health Technology Assessment Analyst Items 5 to 5.2.2

Sana Khan, Health Technology Assessment Analyst Items 6 to 6.2.2

Adam Storrow, Business Analyst, RIA Present for all Items

Benjamin Pearce, Senior Medical Editor Items 1 to 4.2.2

Ria Skelton, Senior Medical Editor Items 5 to 5.2.2

Hayley Garnett, Senior Medical Editor Items 6 to 6.2.2

Ella Livingstone, Technical Adviser, Commercial Risk Assessment Items 5 to 6.2.2

Claire Hawksworth, Technical Analyst, Evidence Generation Items 1 to 5.2.2

Stevie Okoro, Technical Analyst, Commercial Risk Assessment Items 6 to 6.2.2

Laura Marsden, Public Involvement Adviser, PIP Items 1 to 4.1.3

Heidi Livingstone, Public Involvement Adviser, PIP Items 6 to 6.1.3

Catherine Pank, Assistant Project Manager Items 5 to 5.2.2

Nick Cunningham, Coordinator, Corporate Office Items 6 to 6.1.3

Rosalee Mason, Coordinator, Corporate Office Items 1 to 4.1.3

Gemma Smith, Coordinator, COT Present for all Items

Marcia Miller, Administrator, TA Items 1 to 4.2.2 & 6 to 6.2.2

Louise Jones, Administrator, TA Items 5 to 5.2.2

Daniel Greenwood, Assistant Administrator, COT Items 5 to 5.2.2

External review group representatives present

G.J. Melendez-Torres, Peninsula Technology Assessment Group Items 1 to 4.1.3

Rachael Slater, Peninsula Technology Assessment Group Items 1 to 4.1.3

James Mahon, Liverpool Reviews, and Implementation Group Items 5 to 5.1.3

Sophie Beale, Liverpool Reviews, and Implementation Group Items 5 to 5.1.3

Tracey Jhita, BMJ-TAG Items 6 to 6.1.3

Charlotta Karner, BMJ-TAG Items 6 to 6.1.3

Clinical and Patient experts present

Professor Peter Clark, National Clinical lead for Cancer drugs, NHS England, Present for all Items

David Chuter, Patient expert Nominated by Guts UK, Items 1 to 4.1.3 & 5 to 5.1.3

Professor Wasat Mansoor, Professor of Oncology and Consultant in Medical Oncology, Clinical expert nominated by Merck, Sharp & Dohme and Bristol Myers Squibb, Items 1 to 4.1.3 & 5 to 5.1.3

Dr Elizabeth Smyth, Consultant in Gastrointestinal Oncology, Clinical expert nominated by Royal College of Physicians (RCP), Items 1 to 4.1.3 & 5 to 5.1.3

Julie Thompson, Patient expert nominated by Guts UK, Items 1 to 4.1.3 & 5 to 5.1.3

Rachel Downing, Patient expert nominated by Target Ovarian Cancer, Items 6 to 6.1.3

Professor Jonathan Ledermann, Professor of Medical Oncology, Clinical expert Nominated by GSK, Items 6 to 6.1.3

## Minutes

### Introduction to the Meeting

* 1. The chair Dr Jane Adam welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted committee member apologies.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 6 July 2021.

### Appraisal of pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer (ID3741)

* 1. Part 1 – Open Session
		1. The chair welcomed the invited clinical and patient experts, external review group representatives, the national clinical lead for cancer drugs fund, members of the public and company representatives from MSD.
		2. The chair asked all committee members, clinical and patient experts, the national clinical lead for cancer drugs, external review group representatives and NICE staff present to declare any relevant Interests in relation to the Item being considered.
* Nominated Clinical expert Professor Wasat Mansoor declared a financial Interest as he has previously received honoraria for attending an advisory board for MSD.
* It was agreed that his declarations would not prevent Professor Wasat from providing expert advice to the committee.
* Nominated clinical expert Dr Elizabeth Smyth declared financial Interests as she has previously received financial remuneration and/or travel support for meetings from Amal Therapeutics, Astellas, Astra Zeneca, BeIgene, BMS, Celgene, Everest Research, FIve PrIme, GrItstone, Merck, PfIzer, Roche, ServIer and Zymeworks. She Is the chief Investigator of a trial which Is managed by Southampton CTU which has been funded by BMS, her Institution receives funding (either directly or through contract research organisations) for trials on which she Is the Principal Investigator from Astellas, Astra Zeneca, Basilea, Daichi Sankyo, MSD and Roche and she Is the co-chair of the EORTC (European Organization for Research and Treatment of Cancer) Gastric Cancer Taskforce and senior author of the upcoming ESMO Gastric Cancer Guidelines and Oesophageal Cancer Guidelines.
* It was agreed that her declarations would not prevent Dr Smyth from providing expert advice to the committee.
* No further conflicts were declared for this Item.
	+ 1. The chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Jane Adam, Dr Mohit Sharma and Richard Ballerand.
	1. Part 2 – Closed session (company representatives, clinical and patient experts and external review group representatives were asked to leave the meeting)
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) In line with their decisions.

### Appraisal of nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer (ID1465)

* 1. Part 2a – Closed Session (no public observers)
		1. The chair welcomed the invited clinical and Patient experts, external review group representatives and company representatives from BMS.
		2. The chair asked all committee members, clinical and patient experts, external review group representatives, the national clinical lead for cancer drugs fund and NICE staff present to declare any relevant Interests In relation to the Item being considered.
* Nominated clinical expert Professor Wasat Mansoor declared a financial Interest as he has previously received fees from BMS for attending an advisory board.
* It was agreed that his declarations would not prevent Professor Mansoor from providing expert advice to the committee.
* Nominated clinical expert Dr Elizabeth Smyth declared financial Interests as she has previously received financial remuneration and/or travel support for meetings from Amal Therapeutics, Astellas, Astra Zeneca, BeIgene, BMS, Celgene, Everest Research, FIve PrIme, GrItstone, Merck, PfIzer, Roche, ServIer and Zymeworks. She Is the chief Investigator of a trial which Is managed by Southampton CTU which has been funded by BMS, her Institution receives funding (either directly or through contract research organisations) for trials on which she Is the principal Investigator from Astellas, Astra Zeneca, Basilea, Daichi Sankyo, MSD and Roche and she Is the co-chair of the EORTC (European organisation for Research and Treatment of Cancer) gastric Cancer Taskforce and senior author of the upcoming ESMO Gastric Cancer Guidelines and Oesophageal Cancer Guidelines.
* It was agreed that her declarations would not prevent Dr Smyth from providing expert advice to the committee.
* No further conflicts were declared for this Item.
	+ 1. The chair led a discussion of the evidence presented to the committee. This Information was presented to the committee by Professor Khalida Ismail, Professor G.J. Melendez-Torres and Richard Ballerand.
	1. Part 2b – Closed Session (company representatives, clinical and patient experts, and external review group representatives were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) In line with their decisions.

### Appraisal of niraparib for maintenance treatment of relapsed, platinum sensitive ovarian, fallopian tube and peritoneal cancer (ID1644)

* 1. Part 1 – Open Session
		1. The chair welcomed the invited clinical and patient experts, external review group representatives, members of the public and company representatives from GlaxoSmithKline.
		2. The chair asked all committee members, clinical and patient experts, external group representatives, the national clinical lead for cancer drugs fund and NICE staff present to declare any relevant Interests In relation to the Item being considered.
* Committee member Dr Alice Turner declared a financial Interest as she has received consultancy and honoraria fees from GSK In an unrelated area.
* It was agreed that her declaration would not prevent Dr Turner from participating in this section of the meeting.
* Nominated clinical expert Professor Jonathan Ledermann declared financial Interests as he has previously received advisory board and lecture fees from Neopharma, GSK, AstraZeneca, Clovis Oncology, Eisai, MSD, Artios Pharma, Regeneron, VBL Therapeutics and PfIzer. HIs university has received research grants from AstraZeneca and MSD. He was the clinical Investigator on trials with niraparib, olaparib and rucaparib in recurrent ovarian cancer and he Is also editor of Gynaecological Cancer Track, ESMO Clinical Practice Guidelines and Vice President of ESGO.
* It was agreed that his declarations would not prevent Professor Ledermann from providing expert advice to the committee.
* Nominated patient expert Rachel Downing declared financial Interests as Target Ovarian Cancer has received funding from GSK In May 2020 for the nurse-led support line as part of Its response to the coronavirus pandemic. They also received funding In August 2020 from AstraZeneca for the running of Target Ovarian Cancer’s nurse-led support line and online support to women as part of the response to the coronavirus pandemic. Rachel received an honorarium for a speaking engagement from GSK.
* It was agreed that her declarations would not prevent Rachel from providing expert advice to the committee.
	+ 1. The chair led a discussion of the evidence presented to the committee. This Information was presented to the committee by Dr Alice Turner and Hugo Pedder.
	1. Part 2 – Closed Session (company representatives, clinical and patient experts, external review group representatives and members of the public were asked to leave the meeting).
		1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or the Final Appraisal Determination (FAD) In line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 7 September 2021 and will start promptly at 9.30am.